NKGen Biotech, Inc. NKGN
0.06 USD 0.00 (+0.00%)
At closeFeb 5, 2026, 4:00 PM EST
0.18 +0.12 +204.17%
After hours · Feb 5, 4:00 PM ET
0.02 Day range 0.02
0.001 52-week range 0.20
- YTD
- +20.00%
- 1 year
- -79.09%
- Market cap
- 7.84M
- EPS (ttm)
- -1.38
- Shares out
- 35.36M
- YTD return
- +20.00%
- 1-year return
- -79.09%
- Volume
- 200
- Avg volume
- 2.20K
- Open
- 0.02
- Previous close
- 0.06
- Day's range
- 0.02 – 0.02
- 52-week range
- 0.001 – 0.20
- Beta
- 0.52
No chart data for this range yet.
Key statistics
- Enterprise value
- 50.64M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 12.75M
- Total cash
- 79.00K
- Total debt
- 28.09M
- Return on equity
- 0.00%
- Short % of float
- 8.68%
- 50-day average
- 0.3778
- 200-day average
- 0.986875
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
NKGN Revenue — quarterly 0
NKGN Net income — quarterly 6.60M
NKGN EPS — quarterly 0.23
About NKGen Biotech, Inc.
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nkgenbiotech.com
News
NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum 
NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026 
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions 
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support Enrollment 
NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit 
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™ 
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026 
Head to Head Contrast: NKGen Biotech (NYSE:NKGN) and SQZ Biotechnologies (NYSE:SQZ) 
Head to Head Comparison: NKGen Biotech (NYSE:NKGN) versus SQZ Biotechnologies (NYSE:SQZ) 
NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D.
Your note
Sign in to keep a note on NKGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GRAF JAMES A | Chief Financial Officer | Purchase | Dec 3, 2023 | 2,437,440 |
| PARK SANGWOO | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Gift | Dec 12, 2023 | 0 |
| SONG PAUL Y | Chief Executive Officer | Purchase | Dec 6, 2023 | 171,121 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Polar Asset Management Partners Inc. | 3.34% | 1,181,872 | 759.71K | Sep 29, 2024 |
| Meteora Capital, LLC | 2.50% | 884,745 | 568.71K | Sep 29, 2024 |
| University of Chicago | 1.56% | 550,000 | 353.54K | Sep 29, 2024 |
| Diametric Capital, Lp | 1.47% | 518,134 | 333.06K | Sep 29, 2024 |
| Vanguard Group Inc | 0.64% | 227,804 | 146.43K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.32% | 112,714 | 72.45K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.49% | 174,000 | 111.85K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.19% | 67,693 | 43.51K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.15% | 53,804 | 34.59K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.09% | 32,218 | 20.71K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 16,106 | 10.35K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.04% | 15,070 | 9.69K | Oct 30, 2024 |